ISSN: 2630-5720 | E-ISSN: 2687-346X

Quick Search




Comparison of Adenosine Deaminase (ADA) and Cancer Antigen 125 (CA 125) Levels in Epithelial Ovarian Tumors []
. 2019; 59(4): 309-314 | DOI: 10.14744/hnhj.2018.60362

Comparison of Adenosine Deaminase (ADA) and Cancer Antigen 125 (CA 125) Levels in Epithelial Ovarian Tumors

Mustafa Taş1, Zeynep Ece Utkan Korun2, Alper Koçak3, Adem Yavuz4, Bülent Özçelik5, Mete Güngör1, Gökalp Öner4
1Department of Obstetrics and Gynecology, Acıbadem Mehmet Ali Aydınlar University Faculty of Medicine, Istanbul, Turkey
2Department of Obstetrics and Gynecology, Haydarpaşa Numune Training and Research Hospital, Istanbul, Turkey
3Department of Obstetrics and Gynecology, Ömer Halisdemir University Training and Research Hospital, Niğde, Turkey
4Department of Obstetrics and Gynecology, Private Magnet Hospital, Kayseri, Turkey
5Department of Obstetrics and Gynecology, Erciyes University Faculty of Medicine, Kayseri, Turkey

INTRODUCTION: In this study, we aimed to determine serum adenosine deaminase (ADA) and cancer antigen 125 (CA 125) levels in patients with epithelial ovarian tumors.
METHODS: A total of 75 patients with 47 malignant and 28 benign epithelial ovarian tumors were included in this case-control study. On the morning of the operation, serum CA 125 and ADA levels were determined. Postoperative epithelial ovarian tumor patients were divided into two subgroups as benign and malignant histopathologically. We evaluated whether there was a correlation between tumor levels and serum CA-125 and ADA levels of subgroups and malignant patients.
RESULTS: Of 47 patients with malignant epithelial ovarian cancer, 20 of them had an early-stage (stage 1-2) and 27 of them had advanced-stage (stage 3-4) tumors. Serum CA-125 (26.38 vs 44.93, p<0.001) and ADA levels (29.91 vs 42. 82, p≤0.05) were significantly higher in malignant epithelial ovarian tumors than in benign epithelial ovarian tumors. There was no significant correlation between ADA levels.
DISCUSSION AND CONCLUSION: This study showed that serum ADA levels in patients with epithelial ovarian cancer could be used as a biomarker in combination with other parameters for predicting malignancy in ovarian cancer. To validate these clinical data, large-scale studies of epithelial ovarian tumors are needed.

Keywords: Adenosine deaminase, cancer antigen 125; epithelial ovarian cancer.

Mustafa Taş, Zeynep Ece Utkan Korun, Alper Koçak, Adem Yavuz, Bülent Özçelik, Mete Güngör, Gökalp Öner. Comparison of Adenosine Deaminase (ADA) and Cancer Antigen 125 (CA 125) Levels in Epithelial Ovarian Tumors. . 2019; 59(4): 309-314

Corresponding Author: Mustafa Taş, Türkiye
LookUs & Online Makale